NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Edge Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing life-saving hospital products for acute, fatal or debilitating conditions, announced today, enrollment of the first patient in the NEWTON study, a multicenter Phase 1/2 randomized, open-label, controlled clinical study of its lead product, EG-1962 at the University of Maryland Medical Center site in Baltimore, Maryland. The study is evaluating the safety, tolerability, and pharmacokinetics of EG-1962 compared to the current standard of care, oral nimodipine after subarachnoid hemorrhage (SAH). Exploratory endpoints will assess the ability of EG-1962 to reduce delayed cerebral ischemia (DCI) and improve clinical outcome compared to oral nimodipine.
Help employers find you! Check out all the jobs and post your resume.
